Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II).

Tytuł:
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II).
Autorzy:
Maddaloni E; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.; Diabetes Trial Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
D'Onofrio L; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Alessandri F; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Mignogna C; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Leto G; Santa Maria Goretti Hospital, Polo Pontino Sapienza University, Latina, Italy.
Pascarella G; Campus Bio-Medico University of Rome, Rome, Italy.
Mezzaroma I; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Lichtner M; Santa Maria Goretti Hospital, Polo Pontino Sapienza University, Latina, Italy.
Pozzilli P; Campus Bio-Medico University of Rome, Rome, Italy.
Agrò FE; Campus Bio-Medico University of Rome, Rome, Italy.
Rocco M; Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Pugliese F; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Lenzi A; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Holman RR; Diabetes Trial Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Mastroianni CM; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Buzzetti R; Umberto I 'Policlinico' General Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. .
Corporate Authors:
CoViDiab Study Group
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2020 Oct 01; Vol. 19 (1), pp. 164. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2002-
MeSH Terms:
Betacoronavirus*
Cardiovascular Diseases/*diagnosis
Cardiovascular Diseases/*epidemiology
Coronavirus Infections/*diagnosis
Coronavirus Infections/*epidemiology
Diabetes Mellitus/*diagnosis
Diabetes Mellitus/*epidemiology
Pneumonia, Viral/*diagnosis
Pneumonia, Viral/*epidemiology
Aged ; Aged, 80 and over ; COVID-19 ; Cardiovascular Diseases/metabolism ; Coronavirus Infections/metabolism ; Diabetes Mellitus/metabolism ; Female ; Follow-Up Studies ; Humans ; Male ; Metabolic Diseases/diagnosis ; Metabolic Diseases/epidemiology ; Metabolic Diseases/metabolism ; Middle Aged ; Multimorbidity/trends ; Pandemics ; Pneumonia, Viral/metabolism ; Prognosis ; Retrospective Studies ; Risk Factors ; SARS-CoV-2
References:
BMJ Open. 2019 Mar 3;9(3):e024476. (PMID: 30833320)
Lancet. 2009 Oct 24;374(9699):1421-2. (PMID: 19854371)
J Am Heart Assoc. 2020 Sep;9(17):e016948. (PMID: 32633594)
Metabolism. 2020 Sep;110:154317. (PMID: 32673651)
Diabetologia. 2020 Nov;63(11):2486-2487. (PMID: 32632527)
Cardiovasc Diabetol. 2019 Jan 19;18(1):9. (PMID: 30660185)
Intensive Care Med. 2020 Jun;46(6):1105-1108. (PMID: 32347323)
Lancet. 2020 May 30;395(10238):1715-1725. (PMID: 32405103)
Lancet Respir Med. 2020 Apr;8(4):e21. (PMID: 32171062)
J Thromb Haemost. 2020 Jul;18(7):1738-1742. (PMID: 32302438)
Diabetes Res Clin Pract. 2020 Nov;169:108454. (PMID: 32971157)
Diabetes Metab Res Rev. 2016 Feb;32(2):169-75. (PMID: 26484614)
Nat Rev Cardiol. 2019 Feb;16(2):113-130. (PMID: 30250166)
Diabetes Metab Res Rev. 2020 Oct;36(7):e3319. (PMID: 32233013)
JAMA. 2020 Apr 28;323(16):1574-1581. (PMID: 32250385)
Lancet. 2020 May 2;395(10234):1417-1418. (PMID: 32325026)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3. (PMID: 32369736)
Diabetes Metab Res Rev. 2020 Nov;36(8):e3330. (PMID: 32336007)
Diabetes Care. 2020 Jul;43(7):1382-1391. (PMID: 32409504)
JAMA. 2020 May 26;323(20):2052-2059. (PMID: 32320003)
N Engl J Med. 2020 Jul 9;383(2):120-128. (PMID: 32437596)
Metabolism. 2020 Jul;108:154244. (PMID: 32320741)
BMC Med. 2020 Mar 10;18(1):44. (PMID: 32151252)
J Clin Med. 2020 May 11;9(5):. (PMID: 32403217)
N Engl J Med. 2020 Jun 11;382(24):2372-2374. (PMID: 32302078)
Diabetes Care. 2020 Jul;43(7):1378-1381. (PMID: 32409505)
Circulation. 2007 Nov 6;116(19):2119-26. (PMID: 17967769)
J Intern Med. 2020 Aug;288(2):192-206. (PMID: 32348588)
Diabetes Care. 2020 Jul;43(7):1408-1415. (PMID: 32430456)
Nat Commun. 2020 Nov 12;11(1):5749. (PMID: 33184277)
Int J Epidemiol. 2019 Apr 1;48(2):640-653. (PMID: 30561628)
Cardiovasc Diabetol. 2019 Jul 11;18(1):89. (PMID: 31296225)
J Am Coll Cardiol. 2020 Sep 8;76(10):1244-1258. (PMID: 32652195)
Diabetes Metab Res Rev. 2020 Oct;36(7):e33213321. (PMID: 32233018)
Cell Metab. 2013 Jan 8;17(1):20-33. (PMID: 23312281)
JAMA Cardiol. 2020 Jul 1;5(7):831-840. (PMID: 32219363)
Eur Respir J. 2020 May 14;55(5):. (PMID: 32217650)
JAMA. 2020 Jun 2;323(21):2195-2198. (PMID: 32329797)
Diabetes Metab. 2020 Oct;46(5):403-405. (PMID: 32447102)
Cardiovasc Diabetol. 2020 Jun 11;19(1):76. (PMID: 32527257)
Br J Gen Pract. 2011 May;61(586):e262-70. (PMID: 21619750)
Grant Information:
MS 2017_2 International European Foundation for the Study of Diabetes
Contributed Indexing:
Investigator: C Ajassa; R Alban; F Alessandri; F Alessi; R Aronica; V Belvisi; R Buzzetti; M Candy; A Caputi; A Carrara; E Casali; EN Cavallari; G Ceccarelli; L Celani; MR Ciardi; L Coraggio; A Curtolo; C D'Agostino; G D'Ettorre; L D'Onofrio; F De Giorgi; G De Girolamo; V Filippi; L Gnessi; C Luordi; E Maddaloni; CM Mastroianni; I Mezzaroma; C Mignogna; C Moretti; F Pugliese; G Recchia; M Ridolfi; FE Romani; G Russo; F Ruberto; G Savelloni; G Siccardi; A Siena; S Sterpetti; S Valeri; M Vera; L Volpicelli; M Watanabe; M Aiuti; G Campagna; C Del Borgo; L Fondaco; B Kertusha; F Leonetti; G Leto; M Lichtner; R Marocco; R Masala; P Zuccalà; FE Agrò; G Nonnis; G Pascarella; P Pozzilli; A Rigoli; A Strumia; D Alampi; M Rocco
Keywords: COPD; Covid-19; Diabetes; Hypertension; SARS-CoV-2
Entry Date(s):
Date Created: 20201002 Date Completed: 20201016 Latest Revision: 20240329
Update Code:
20240329
PubMed Central ID:
PMC7528157
DOI:
10.1186/s12933-020-01140-2
PMID:
33004045
Czasopismo naukowe
Background: Cardiometabolic disorders may worsen Covid-19 outcomes. We investigated features and Covid-19 outcomes for patients with or without diabetes, and with or without cardiometabolic multimorbidity.
Methods: We collected and compared data retrospectively from patients hospitalized for Covid-19 with and without diabetes, and with and without cardiometabolic multimorbidity (defined as ≥ two of three risk factors of diabetes, hypertension or dyslipidaemia). Multivariate logistic regression was used to assess the risk of the primary composite outcome (any of mechanical ventilation, admission to an intensive care unit [ICU] or death) in patients with diabetes and in those with cardiometabolic multimorbidity, adjusting for confounders.
Results: Of 354 patients enrolled, those with diabetes (n = 81), compared with those without diabetes (n = 273), had characteristics associated with the primary composite outcome that included older age, higher prevalence of hypertension and chronic obstructive pulmonary disease (COPD), higher levels of inflammatory markers and a lower PaO2/FIO2 ratio. The risk of the primary composite outcome in the 277 patients who completed the study as of May 15 th , 2020, was higher in those with diabetes (Adjusted Odds Ratio ( adj OR) 2.04, 95%CI 1.12-3.73, p = 0.020), hypertension ( adj OR 2.31, 95%CI: 1.37-3.92, p = 0.002) and COPD ( adj OR 2.67, 95%CI 1.23-5.80, p = 0.013). Patients with cardiometabolic multimorbidity were at higher risk compared to patients with no cardiometabolic conditions ( adj OR 3.19 95%CI 1.61-6.34, p = 0.001). The risk for patients with a single cardiometabolic risk factor did not differ with that for patients with no cardiometabolic risk factors ( adj OR 1.66, 0.90-3.06, adj p = 0.10).
Conclusions: Patients with diabetes hospitalized for Covid-19 present with high-risk features. They are at increased risk of adverse outcomes, likely because diabetes clusters with other cardiometabolic conditions.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies